The funding round was led by Enavate Sciences, a portfolio company created by Patient Square Capital. The round also saw participation of Gaingels, along with other undisclosed investors.
Applying Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology, the partnership intends to develop intravitreal AAV capsids matching a capsid profile defined by Roche. As per the
Under the two-year sponsored research alliance, the companies will work to identify new drug candidates that enable inhibition of two proteins, Bax and Bak. These proteins are integral
Under the terms of the deal, the company will be responsible for the supply of 2.5 million additional doses of liquid frozen Jynneos vaccines. The latest move follows
Discovered and developed by SK Biopharmaceuticals and SK life science, cenobamate is an anti-seizure medication (ASM). It is already approved and available in Europe and the US to treat
The drug is approved and available in the US and Europe to treat partial-onset seizures in adults. As per the terms of the agreement, SK Biopharmaceuticals has granted
The therapy, which has been studied in various Phase I and II clinical trials, demonstrated the potential to amplify T cells across the subsets, improve the immune system,
Orion Biotechnology Canada is a drug discovery company targeting earlier undruggable GPCRs. A biotech firm, Peptilogics is into engineering peptide therapeutics by bringing together computation and biology to
New investors Sands Capital and Vivo Capital have jointly led the financing round, which has also seen participation from new investor Dreavent 6. Sofinnova Partners, New York City
The company is a joint venture between WuXi Biologics and WuXi STA and provides end-to-end contract research, development, and manufacturing of bioconjugates, such as ADCs. Under the terms
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.